ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

摘要:

Clinical trial data have shown that the bisphosphonates pamidronic acid and clodronic acid can reduce the overall incidence of skeletal complications in women with metastatic breast cancer. In addition, both agents delay the onset of skeletal complications, promote bone healing, and have a positive effect on bone pain. Now, 3 economic analyses have found that pamidronic acid and clodronic acid provide substantial benefits at a reasonable cost to the healthcare systems in Italy and Poland. The results of these trials were presented at the ISPOR*3rd Annual European Conference [Antwerp, Belgium; November 2000].

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

摘要:

The problem of mealtime hyperglycaemia is reduced in patients with type 2 diabetes mellitus who receive nateglinide, according to new research presented at the 17th Congress of the International Diabetes Federation [Mexico City, Mexico; November 2000]. Novartis' nateglinide ['Starlix'] is a derivative of the amino acid D-phenylalanine and is chemically distinct from other oral antihyperglycaemics. It is the first of a new class of oral insulin secretion stimulators that target mealtime (postprandial) hyperglycaemia. The rapid absorption and fast elimination of nateglinide enables it to be taken immediately before meals thus avoiding postprandial hyperglycaemia and between-meal hypoglycaemia.

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS